{"pmid":32320812,"title":"[Breast cancer management during the COVID 19 pandemic: the CNGOF takes action].","text":["[Breast cancer management during the COVID 19 pandemic: the CNGOF takes action].","Gynecol Obstet Fertil Senol","Mathelin, Carole","Nisand, Israel","32320812"],"journal":"Gynecol Obstet Fertil Senol","authors":["Mathelin, Carole","Nisand, Israel"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320812","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.gofs.2020.04.008","keywords":["breast cancer","cngof","cancer du sein","covid-19"],"source":"PubMed","weight":0,"_version_":1664815087807889408,"score":8.518259,"similar":[{"pmid":32315805,"title":"[Breast cancer management during the COVID 19 pandemic: the CNGOF takes action].","text":["[Breast cancer management during the COVID 19 pandemic: the CNGOF takes action].","Gynecol Obstet Fertil Senol","Mathelin, Carole","Nisand, Israel","32315805"],"journal":"Gynecol Obstet Fertil Senol","authors":["Mathelin, Carole","Nisand, Israel"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315805","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.gofs.2020.04.009","keywords":["breast cancer","cngof","cancer du sein","covid-19"],"source":"PubMed","weight":0,"_version_":1664714520139923459,"score":377.71545},{"pmid":32278467,"pmcid":"PMC7118684","title":"[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the College Nationale des Gynecologues et Obstetriciens Francais (CNGOF), the Societe d'Imagerie de la FEMme (SIFEM), the Societe Francaise de Chirurgie Oncologique (SFCO), the Societe Francaise de Senologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)].","text":["[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the College Nationale des Gynecologues et Obstetriciens Francais (CNGOF), the Societe d'Imagerie de la FEMme (SIFEM), the Societe Francaise de Chirurgie Oncologique (SFCO), the Societe Francaise de Senologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)].","Bull Cancer","Gligorov, Joseph","Bachelot, Thomas","Pierga, Jean-Yves","Antoine, Eric-Charles","Balleyguier, Corinne","Barranger, Emmanuel","Belkacemi, Yazid","Bonnefoi, Herve","Bidard, Francois-Clement","Ceugnart, Luc","Classe, Jean-Marc","Cottu, Paul","Coutant, Charles","Cutuli, Bruno","Dalenc, Florence","Darai, Emile","Dieras, Veronique","Dohollou, Nadine","Giacchetti, Sylvie","Goncalves, Anthony","Hardy-Bessard, Anne-Claire","Houvenaeghel, Gilles","Jacquin, Jean-Philippe","Jacot, William","Levy, Christelle","Mathelin, Carole","Nisand, Israel","Petit, Thierry","Petit, Thierry","Poncelet, Edouard","Rivera, Sofia","Rouzier, Roman","Salmon, Remy","Scotte, Florian","Spano, Jean-Philippe","Uzan, Catherine","Zelek, Laurent","Spielmann, Marc","Penault-Llorca, Frederique","Namer, Moise","Delaloge, Suzette","32278467"],"journal":"Bull Cancer","authors":["Gligorov, Joseph","Bachelot, Thomas","Pierga, Jean-Yves","Antoine, Eric-Charles","Balleyguier, Corinne","Barranger, Emmanuel","Belkacemi, Yazid","Bonnefoi, Herve","Bidard, Francois-Clement","Ceugnart, Luc","Classe, Jean-Marc","Cottu, Paul","Coutant, Charles","Cutuli, Bruno","Dalenc, Florence","Darai, Emile","Dieras, Veronique","Dohollou, Nadine","Giacchetti, Sylvie","Goncalves, Anthony","Hardy-Bessard, Anne-Claire","Houvenaeghel, Gilles","Jacquin, Jean-Philippe","Jacot, William","Levy, Christelle","Mathelin, Carole","Nisand, Israel","Petit, Thierry","Petit, Thierry","Poncelet, Edouard","Rivera, Sofia","Rouzier, Roman","Salmon, Remy","Scotte, Florian","Spano, Jean-Philippe","Uzan, Catherine","Zelek, Laurent","Spielmann, Marc","Penault-Llorca, Frederique","Namer, Moise","Delaloge, Suzette"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278467","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.bulcan.2020.03.008","keywords":["breast cancer","cancer du sein","covid-19","guidelines","recommandation","sars-cov-2"],"source":"PubMed","weight":0,"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"_version_":1664636873264332800,"score":178.97006},{"pmid":32247066,"pmcid":"PMC7118621","title":"Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","text":["Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.","J Gynecol Obstet Hum Reprod","Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril","32247066"],"abstract":["INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance."],"journal":"J Gynecol Obstet Hum Reprod","authors":["Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247066","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jogoh.2020.101729","keywords":["covid-19","guideline","gynaecological cancer","management"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["ovarian"],"_version_":1664638040194154496,"score":66.2734},{"pmid":32222433,"pmcid":"PMC7103920","title":"[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","text":["[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus.","Gynecol Obstet Fertil Senol","Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C","32222433"],"abstract":["INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus."],"journal":"Gynecol Obstet Fertil Senol","authors":["Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222433","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.gofs.2020.03.017","keywords":["COVID-19","Cancer gynecologique","Guideline","Gynaecological cancer","Management","Prise en charge","Recommandation"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment"],"weight":1,"_version_":1663352135224393728,"score":62.005127},{"pmid":32268374,"title":"Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","text":["Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","J Travel Med","Speth, Robert C","32268374"],"journal":"J Travel Med","authors":["Speth, Robert C"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268374","week":"202015|Apr 06 - Apr 12","doi":"10.1093/jtm/taaa045","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664637635998515200,"score":59.228844}]}